Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

AdvaMed 2012

Summary

Related Content

New Dental Industry Compliance Standards Take Shape: Dental Trade Alliance (DTA) Releases Revised Code of Ethics

State Drug Transparency Laws — 2025 Update

Prescription Drug Affordability Review Boards — 2025 Update

Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy

A Look Ahead in Life Sciences: What We Are Tracking in the Second Quarter of 2025 and Beyond

Goodwin’s 2025 Rare Disease Symposium: Momentum Builds for Addressing Critical Diagnosis and Treatment Gaps

How the Trump Administration Could Reshape Regulation in the Life Sciences Sector

A Look Ahead in Life Sciences: What We Are Tracking in the First Quarter of 2025 and Beyond

Chambers USA 2025 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Blueprint Medicines To Be Acquired By Sanofi For $9.5 Billion Including Contingent Value Rights

Trump’s Drug Price Plan Seeks Leverage with FDA Withdrawal Power (Bloomberg Law)

Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

Preparing for the US Biosecure Act - What Does It Mean for the Pharma Industry? (Outsourcing Pharma)

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Life Sciences

Life Sciences Regulatory & Compliance